Migalastat HCl | Galactosidase inhibitor/Pharmacological chaperone

Migalastat chemical structure Focus Biomolecules

Available Options

Size:PriceQuantity 
1 mg$40.00
5 mg$160.00
Request Quote / Bulk / Custom Size
Product Inquiry

Migalastat (75172-81-5) is a potent, selective, and orally available inhibitor of α-galactosidase A (IC50= 40 nM).1 It binds to mutant misfolded α-GalA shifting the folding behavior toward functional active conformation (pharmacological chaperone activity) followed by trafficking to the lysosomes.2 Migalastat is active broadly across species from Drosophila3 to human4. Clinically useful agent for Fabry disease.5

References/Citations:

  1. Asano et al. (2000), In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives; Eur. J. Biochem. 267 4179
  2. Siekierska et al. (2012), α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants; J. Biol. Chem. 287 28386
  3. Braunstein et al. (2020), Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat; Int. J. Mol. Sci. 21 7397
  4. Benjamin et al. (2009), The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines; J. Inherit. Metab. Dis. 32 424
  5. McCafferty and Scott (2019), Migalastat: A Review in Fabry Disease; Drugs 79 543
1-Deoxygalactonojirimycin, 75172-81-5, alpha-galactosidase A inhibitor, AT1001, GR181413, Migalastat, Migalastat HCl supplier, Migalastat supplier, α-galactosidase A inhibitor
Alternate Name:
1-Deoxygalactonojirimycin HCl; DGJ; GR181413; AT1001

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Migalastat (75172-81-5) is a potent, selective, and orally available inhibitor of α-galactosidase A (IC50= 40 nM).1 It binds to mutant misfolded α-GalA shifting the folding behavior toward functional active conformation (pharmacological chaperone activity) followed by trafficking to the lysosomes.2 Migalastat is active broadly across species from Drosophila3 to human4. Clinically useful agent for Fabry disease.5

References/Citations:

  1. Asano et al. (2000), In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives; Eur. J. Biochem. 267 4179
  2. Siekierska et al. (2012), α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants; J. Biol. Chem. 287 28386
  3. Braunstein et al. (2020), Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat; Int. J. Mol. Sci. 21 7397
  4. Benjamin et al. (2009), The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines; J. Inherit. Metab. Dis. 32 424
  5. McCafferty and Scott (2019), Migalastat: A Review in Fabry Disease; Drugs 79 543